somewhat the same economics to you of a pro-active, ex-ante, though not perfect risk reduction method, an rMNA vaccine, versus the monoclonal antibodies after the fact, post-ante, treatment method, in hopes that one gets the treatment in time.
its all about an individual's risk preferences and choices. .
|